X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs DISHMAN PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES DISHMAN PHARMA DIVIS LABORATORIES/
DISHMAN PHARMA
 
P/E (TTM) x 28.8 25.1 115.0% View Chart
P/BV x 5.0 3.3 149.3% View Chart
Dividend Yield % 1.0 0.7 149.3%  

Financials

 DIVIS LABORATORIES   DISHMAN PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
DISHMAN PHARMA
Mar-16
DIVIS LABORATORIES/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,222374 326.4%   
Low Rs784129 608.2%   
Sales per share (Unadj.) Rs153.1197.8 77.4%  
Earnings per share (Unadj.) Rs39.921.2 188.4%  
Cash flow per share (Unadj.) Rs44.634.7 128.4%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.00.8 125.4%  
Book value per share (Unadj.) Rs201.8179.9 112.2%  
Shares outstanding (eoy) m265.4780.69 329.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.61.3 514.9%   
Avg P/E ratio x25.111.9 211.6%  
P/CF ratio (eoy) x22.57.2 310.4%  
Price / Book Value ratio x5.01.4 355.3%  
Dividend payout %25.09.4 265.4%   
Avg Mkt Cap Rs m266,26620,306 1,311.3%   
No. of employees `0009.70.8 1,174.3%   
Total wages/salary Rs m4,6875,355 87.5%   
Avg. sales/employee Rs Th4,175.019,252.7 21.7%   
Avg. wages/employee Rs Th481.56,459.5 7.5%   
Avg. net profit/employee Rs Th1,089.32,064.1 52.8%   
INCOME DATA
Net Sales Rs m40,64315,961 254.6%  
Other income Rs m749265 282.2%   
Total revenues Rs m41,39216,226 255.1%   
Gross profit Rs m14,4604,103 352.4%  
Depreciation Rs m1,2331,091 113.1%   
Interest Rs m23944 2.4%   
Profit before tax Rs m13,9532,334 597.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,349624 537.1%   
Profit after tax Rs m10,6041,711 619.7%  
Gross profit margin %35.625.7 138.4%  
Effective tax rate %24.026.7 89.8%   
Net profit margin %26.110.7 243.4%  
BALANCE SHEET DATA
Current assets Rs m40,10511,018 364.0%   
Current liabilities Rs m6,5959,517 69.3%   
Net working cap to sales %82.59.4 876.8%  
Current ratio x6.11.2 525.3%  
Inventory Days Days119110 107.3%  
Debtors Days Days8135 231.6%  
Net fixed assets Rs m19,99516,304 122.6%   
Share capital Rs m531161 328.9%   
"Free" reserves Rs m53,04312,907 411.0%   
Net worth Rs m53,57414,516 369.1%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m61,58529,805 206.6%  
Interest coverage x618.43.5 17,816.5%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.70.5 123.2%   
Return on assets %17.38.9 193.7%  
Return on equity %19.811.8 167.9%  
Return on capital %26.117.5 148.8%  
Exports to sales %024.8 0.0%   
Imports to sales %25.23.7 675.6%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs m10,259596 1,720.5%   
Fx inflow Rs m35,3844,952 714.6%   
Fx outflow Rs m10,399697 1,492.3%   
Net fx Rs m24,9854,255 587.2%   
CASH FLOW
From Operations Rs m11,4932,786 412.5%  
From Investments Rs m-11,372-1,529 743.8%  
From Financial Activity Rs m-93-941 9.9%  
Net Cashflow Rs m28316 9.0%  

Share Holding

Indian Promoters % 52.0 61.4 84.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 3.7 318.9%  
FIIs % 19.0 12.7 149.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 22.1 77.8%  
Shareholders   31,796 46,261 68.7%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT LTD.  GSK PHARMA  PANACEA BIOTECH  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 21, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS